Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 16Completed 16Active not recruiting 9Terminated 8Withdrawn 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Triple Negative Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Neoplasms 7Head and Neck Neoplasms 7Multiple Myeloma 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 5Lung Neoplasms 4Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Kidney Neoplasms 2Inflammatory Breast Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Urothelial Cancer 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Spinocerebellar Degenerations 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × pembrolizumab × Clear all
NCT03873025 2021-08-17

PLACARD

University College, London

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03605589 2021-04-01

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Children's Hospital Medical Center, Cincinnati

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04279938 2020-02-21

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Royal Marsden NHS Foundation Trust

Phase 1 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡